Table 4 Dyslipidemia and TG/HDL-C ratio in classes of DILI and control group.

DILI

5.07 ± 2.93

1.99 ± 1.26

1.03 ± 0.53

2.79 ± 2.37

68.98 ± 32.48

3.26 ± 4.17

Control

4.28 ± 0.99

 < 0.01

1.29 ± 0.85

 < 0.01

1.15 ± 0.33

 < 0.01

2.54 ± 0.75

0.14

45.64 ± 26.52

 < 0.01

1.8 ± 8.51

0.02

HBV

4.04 ± 1.27

 < 0.01

1.47 ± 0.82

 < 0.01

0.99 ± 0.48

0.34

2.08 ± 0.76

 < 0.01

68.08 ± 33

0.76

2.73 ± 5.05

0.22

Classes of drugs

 Chinese herbal medicines

4.83 ± 3.3

 > 0.05

2.01 ± 1.11

 > 0.05

0.94 ± 0.52^b

2.57 ± 2.67

 > 0.05

72.29 ± 32.69

 > 0.05

3.75 ± 4.42^a

 Western medicines

5.49 ± 2.55

1.79 ± 1.42

1.19 ± 0.5^a

3.1 ± 1.96

63.81 ± 32.16

2.38 ± 3.85^b

 Both

4.94 ± 2.26

2.35 ± 1.32

1 ± 0.58^ab

2.83 ± 2.06

69.06 ± 31.9

3.53 ± 3.72^ab

Patterns of liver injury

Hepatocellular

4.31 ± 1.6^bc

1.81 ± 1.09

 > 0.05

0.98 ± 0.44

 > 0.05

2.3 ± 1.44^b

73.76 ± 34.43

 > 0.05

2.96 ± 3.78

 > 0.05

Cholestatic

5.9 ± 3.76^a

2.16 ± 1.46

1.11 ± 0.62

3.36 ± 3.02^a

65.75 ± 31.52

3.48 ± 4.63

Mix

4.38 ± 1.68^b

1.88 ± 0.87

0.92 ± 0.46

2.21 ± 1.37^bc

66.58 ± 29.32

3.35 ± 3.59

Severity of DILI

Level 0–2

4.79 ± 1.69

0.12

1.62 ± 0.7

 < 0.01

1.22 ± 0.5

 < 0.01

2.54 ± 1.02

0.11

62.34 ± 31.89

 < 0.01

1.64 ± 1.03

 < 0.01

Level ≥ 3

5.63 ± 4.92

2.72 ± 1.2

0.65 ± 0.42

3.28 ± 4.18

82.45 ± 33.29

6.55 ± 5.43